Abstract：Objective To study the clinical effect and safety of dexmedetomidine in children with agitation during ventilator weaning. Methods A prospective open observational study was performed for children who were admitted to the intensive care unit and experienced mechanical ventilation between March 2017 and August 2018. They were given dexmedetomidine due to the failure in the spontaneous breathing test (SBT) caused by agitation. A sedation-agitation scale score of ≥ 5 was defined as agitation. The children were observed in terms of the sedation state at 0.5, 1, 2, 6, and 12 hours after the administration of dexmedetomidine, blood gas parameters before extubation and at 1, 24, and 48 hours after extubation, vital signs (heart rate, respiratory rate and mean arterial pressure) before SBT, before extubation, and at 10, 60, and 120 minutes and 24 hours after extubation, and incidence rates of adverse events related to the use of dexmedetomidine. Results A total of 19 children were enrolled in this study. All the children were in a state of agitation at the time of enrollment. At 0.5, 1, 2, 6, and 12 hours after the administration of dexmedetomidine, 12, 17, 17, 18, and 18 children respectively reached the sedation state. There were no significant differences in the oxygenation index, arterial partial pressure of carbon dioxide, heart rate, respiratory rate, and mean arterial pressure at each time point before and after extubation (P > 0.05). No adverse events were observed, such as severe hypotension and respiratory depression, and only one child experienced reversible bradycardia. Conclusions Dexmedetomidine is safe and effective in children with agitation during ventilator weaning, but prospective randomized controlled trials are needed for verification.
HE Jie,ZHANG Xin-Ping,YANG Mei-Yu et al. Application of dexmedetomidine in children with agitation during ventilator weaning[J]. CJCP, 2019, 21(6): 522-527.
Motta E, Luglio M, Delgado AF, et al. Importance of the use of protocols for the management of analgesia and sedation in pediatric intensive care unit[J]. Rev Assoc Med Bras (1992), 2016, 62(6):602-609.
[2]
Harris J, Ramelet AS, van Dijk M, et al. Clinical recommendations for pain, sedation, withdrawal and delirium assessment in critically ill infants and children:an ESPNIC position statement for healthcare professionals[J]. Intensive Care Med, 2016, 42(6):972-986.
[3]
Parker AM, Sricharoenchai T, Raparla S, et al. Posttraumatic stress disorder in critical illness survivors:a meta analysis[J]. Crit Care Med, 2015, 43(5):1121-1129.
[4]
Girard TD, Alhazzani W, Kress JP, et al. An Official American Thoracic Society/American College of Chest Physicians Clinical Practice Guideline:liberation from mechanical ventilation in critically ill adults. Rehabilitation protocols, ventilator liberation protocols, and cuff leak tests[J]. Am J Respir Crit Care Med, 2017, 195(1):120-133.
[5]
Chen K, Lu Z, Xin YC, et al. Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patients[J]. Cochrane Database Syst Rev, 2015, 1:CD010269.
[6]
Plambech MZ, Afshari A. Dexmedetomidine in the pediatric population:a review[J]. Minerva Anestesiol, 2015, 81(3):320-332.
[7]
Banasch HL, Dersch-Mills DA, Boulter LL, et al. Dexmedetomidine use in a pediatric intensive care unit:a retrospective cohort study[J]. Ann Pharmacother, 2018, 52(2):133-139.
[8]
Riker RR, Fraser GL, Cox PM, et al. Continuous infusion of haloperidol controls agitation in critically ill patients[J]. Crit Care Med, 1994, 22(3):433-440.
Riker RR, Picard JT, Fraser GL, et al. Prospective evaluation of the Sedation-Agitation Scale for adult critically ill patients[J]. Crit Care Med, 1999, 27(7):1325-1329.
[11]
Constantin JM, Momon A, Mantz J, et al. Efficacy and safety of sedation with dexmedetomidine in critical care patients:a meta-analysis of randomized controlled trials[J]. Anaesth Crit Care Pain Med, 2016, 35(1):7-15.
Pun BT, Ely EW. The importance of diagnosing and managing ICU delirium[J]. Chest, 2007, 132(2):624-636.
[14]
Pun BT, Devlin JW. Delirium monitoring in the ICU:strategies for initiating and sustaining screening efforts[J]. Semin Respir Crit Care Med, 2013, 34(2):179-188.
[15]
Traube C, Silver G, Gerber LM, et al. Delirium and mortality in critically ill children:epidemiology and outcomes of pediatric delirium[J]. Crit Care Med, 2017, 45(5):891-898.
Shehabi Y, Nakae H, Hammond N, et al. The effect of dexmedetomidine on agitation during weaning of mechanical ventilation in critically ill patients[J]. Anaesth Intensive Care, 2010, 38(1):82-90.
Grant MJ, Schneider JB, Asaro LA, et al. Dexmedetomidine use in critically ill children with acute respiratory failure[J]. Pediatr Crit Care Med, 2016, 17(12):1131-1141.
[21]
Weerink MAS, Struys MMRF, Hannivoort LN, et al. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine[J]. Clin Pharmacokinet, 2017, 56(8):893-913.
Ng KT, Shubash CJ, Chong JS. The effect of dexmedetomidine on delirium and agitation in patients in intensive care:systematic review and meta-analysis with trial sequential analysis[J]. Anaesthesia, 2018, 74(3):380-392.
[24]
Roosens E, Mulier JP, Heylens G, et al. The use of dexmedetomidine in extreme agitation[J]. Tijdschr Psychiatr, 2017, 59(9):554-558.
